AQR Capital Management LLC Sells 36,554 Shares of Enfusion, Inc. (NYSE:ENFN)

AQR Capital Management LLC reduced its position in shares of Enfusion, Inc. (NYSE:ENFN) by 63.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,819 shares of the company’s stock after selling 36,554 shares during the period. AQR Capital Management LLC’s holdings in Enfusion were worth $177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ENFN. Allspring Global Investments Holdings LLC bought a new stake in shares of Enfusion during the first quarter worth about $44,000. RiverPark Advisors LLC acquired a new stake in Enfusion during the 2nd quarter valued at approximately $68,000. Arizona State Retirement System acquired a new stake in Enfusion during the 2nd quarter valued at approximately $86,000. Price T Rowe Associates Inc. MD acquired a new stake in Enfusion during the 1st quarter valued at approximately $102,000. Finally, Quadrature Capital Ltd acquired a new stake in Enfusion during the 1st quarter valued at approximately $109,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Stock Performance

NYSE:ENFN opened at $8.77 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of 292.17, a P/E/G ratio of 2.49 and a beta of 0.92. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $10.45. The company has a 50 day simple moving average of $8.56 and a two-hundred day simple moving average of $8.88.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Enfusion had a return on equity of 6.17% and a net margin of 1.98%. The business had revenue of $49.46 million for the quarter, compared to the consensus estimate of $50.27 million. Research analysts predict that Enfusion, Inc. will post 0.07 EPS for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.